The NHS-Galleri trial's reported 20%+ drop in stage 4 cancers among 142,000 participants represents the first large-scale randomized evidence that a multi-cancer early detection (MCED) blood test can shift diagnoses away from the most lethal presentations, even as the primary endpoint for combined stage 3-4 reduction went unmet. This 50-77 age cohort RCT, with three annual blood draws, outperformed observational MCED studies like the DETECT-A trial (n=10,006) by demonstrating temporal strengthening of the stage 4 benefit by year three, yet it leaves unaddressed the original coverage's silence on false-positive rates, diagnostic workup burden, and equity across England's eight regions. A critical omission is the absence of peer-reviewed publication details; preliminary results echo patterns from GRAIL's earlier PATHFINDER study (n=6,662, observational) where specificity reached 99.5% but positive predictive value hovered near 40%, raising questions about overdiagnosis in lower-prevalence populations. Conflicts of interest loom large: co-investigator ties to GRAIL and Illumina, the test's commercial developers, mirror industry funding patterns seen in the 2023 Lancet Oncology Galleri interim report. Synthesizing these with the current data suggests MCED could complement existing screens like FIT and mammography, but only if future analyses quantify lead-time bias and mortality—not just stage shift—outcomes. The trial's scale dwarfs prior efforts, yet without full cost-effectiveness modeling, rollout risks widening disparities for underserved groups.